Favorable government regulations in North America regional market authorizes monoclonal antibodies during the onset of the pandemic. For instance, in December 2021, The US Food and Drug Administration (FDA) announced Emergency Use Authorization (EUA) for AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab and administered together) intended for pre-exposure prophylaxis of COVID-19 for certain adults and pediatric individuals. As monoclonal antibodies are laboratory manufactured proteins involved in mimicking the immune system's ability to fight off harmful pathogens such as viruses. Therefore, "Tixagevimab" and "cilgavimab" are long-acting monoclonal antibodies particularly directed for spike protein of SARS-CoV-2. Apart from that, favorable funding for development of biologics further enhanced the market growth for monoclonal antibodies during the onset of pandemic in North America regional market. For example, the US International Development Finance Corporation (DFC) announced furnishing of US$50 million to Biological E Limited for increasing COVID-19 vaccine manufacturing capacity. Also, favorable policy relating to product approvals for biologics by the FDA positively impacts the market growth.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the monoclonal antibodies market. The North America monoclonal antibodies market is expected to grow at a good CAGR during the forecast period.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 54,629.4 Million |
| Market Size by 2028 | US$ 1,20,713.2 Million |
| CAGR (2021 - 2028) | 12.0% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Source
|
| Regions and Countries Covered |
North America
|
| Market leaders and key company profiles |
|
The North America Monoclonal Antibodies Market is valued at US$ 54,629.4 Million in 2021, it is projected to reach US$ 1,20,713.2 Million by 2028.
As per our report North America Monoclonal Antibodies Market, the market size is valued at US$ 54,629.4 Million in 2021, projecting it to reach US$ 1,20,713.2 Million by 2028. This translates to a CAGR of approximately 12.0% during the forecast period.
The North America Monoclonal Antibodies Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Monoclonal Antibodies Market report:
The North America Monoclonal Antibodies Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Monoclonal Antibodies Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Monoclonal Antibodies Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Monoclonal Antibodies Market
